Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6605220 | 0.84 | KMT2A (0.42) | ALDH1A1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL7425562 | 0.80 | ALDH1A1 (0.43) | ALDH1A1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL6605704 | 0.80 | MAPK1 (0.46) | ALDH1A1KMT2AKDM4ESMN1; SMN2HPGD | |
| SCHEMBL7050093 | 0.77 | PDE4A (0.48) | ALDH1A1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL6609206 | 0.76 | ALDH1A1 (0.45) | ALDH1A1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL7429380 | 0.74 | ALDH1A1 (0.38) | ALDH1A1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL8005492 | 0.74 | KMT2A (0.43) | ALDH1A1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL7055321 | 0.74 | MAPT (0.43) | ALDH1A1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL7055317 | 0.74 | MAPT (0.43) | ALDH1A1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL7055316 | 0.74 | MAPT (0.43) | ALDH1A1KMT2AMAPTKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257548-B1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2004-05-06 | — | — | EP | disclosed |
| EP-1257548-A1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | Darwin Discovery Limited (GB) | 2002-11-20 | — | — | EP | disclosed |
| US-6455561-B1 | ADMINISTERING BENZOFURAN DERIVATIVE FOR THERAPY OF DISEASE STATE THAT IS CAPABLE OF BEING MODULATED BY INHIBITION OF PHOSPHODIESTERASE IV OR TUMOUR NECROSIS FACTOR | DARWIN DISCOVERY, LTD. (GB) | 2002-09-24 | — | — | US | disclosed |
| US-20020022645-A1 | Heterocyclic compounds and their therapeutic use | DYKE HAZEL JOAN (GB) | 2002-02-21 | — | — | US | disclosed |
| US-6331556-B2 | BENZOFURAN-4-CARBOXYLIC ACID AMIDE DERIVATIVES USED AS PHOSPHODIESTERASE IV OR TUMOR NECROSIS FACTOR INHIBITORS | DARWIN DISCOVERY, LTD. (GB) | 2001-12-18 | — | — | US | disclosed |
| US-20010031777-A1 | Heterocyclic compounds and their therapeutic use | DARWIN DISCOVERY LIMITED (GB) | 2001-10-18 | — | — | US | disclosed |
| WO-2001058895-A1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031777-A1 | Heterocyclic compounds and their therapeutic use | CYP2F1, CYP11B2, CYP3A7 | ALDH1A1 942/4885KMT2A 2401/4885MAPT 3923/4885 |
| US-20020022645-A1 | Heterocyclic compounds and their therapeutic use | EPX, MPO, PDE3B | ALDH1A1 379/4885KMT2A 3514/4885MAPT 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.